
|Videos|May 18, 2017
Dr. Kumar Discusses Daratumumab in Multiple Myeloma
Author(s)Shaji K. Kumar, MD
Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab in multiple myeloma.
Advertisement
Shaji K. Kumar, MD, professor of Medicine, Mayo Clinic, discusses daratumumab (Darzalex) in multiple myeloma.
The first monoclonal antibodies have been approved for use in multiple myeloma. Daratumumab, a monoclonal antibody, binds to CD38, which is overexpressed by multiple myeloma cells.
The results seen with daratumumab have been quite striking, says Kumar. There have been 2 large phase III trials, both of which showed adding daratumumab to regularly used regimens improved progression-free survival.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































